Glucagon-like peptide-1 receptor agonist (GLP-1 RA) is a new class of hypoglycemic drugs, which is increasingly important in the treatment of type 2 diabetes mellitus (T2DM) due to its outstanding effects of hypoglycemia, weight loss and low risk of hypoglycemia. Over the past several years, the developer has completed seven cardiovascular outcome trial (CVOT) involving liraglutide, once-weekly long-acting exenatide, lixisenatide, abirlutide, duraglutide, semaglutide as a subcutaneous injection, and semaglutide as an oral formulation. The cardiovascular outcomes of all GLP-1 RAs were found to be noninferior to placebo, and some GLP-1 RAs were found to be superior. The results of these trials have changed national guidelines for medical treatment of T2DM. This article reviewed 7 CVOTs of GLP-1 RAs, in order to provide more support for clinical medication.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |